JG
ALXN

Jefferies Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Jefferies Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29,400
Closed -$3.36M – 1896
2020
Q3 		$3.36M Buy
29,400
+800
+3% +$86.3K 0.04% 385
2020
Q2 		$3.21K Sell
28,600
-60,900
-68% -$6.47M 0.04% 395
2020
Q1 		$7.81M Buy
89,500
+6,100
+7% +$599K 0.09% 199
2019
Q4 		$9.02M Sell
83,400
-20,200
-19% -$2.16M 0.07% 263
2019
Q3 		$10.1M Buy
103,600
+64,600
+166% +$7.28M 0.08% 219
2019
Q2 		$5.11M Buy
39,000
+30,000
+333% +$3.87M 0.04% 465
2019
Q1 		$1.22M Buy
+9,000
New +$1.12M 0.01% 1175
2018
Q3 		– Sell
-142,500
Closed -$17.7M – 2865
2018
Q2 		$17.7M Buy
+142,500
New +$16.7M 0.1% 131
2017
Q4 		– Sell
-57,500
Closed -$8.07M – 2924
2017
Q3 		$8.07M Buy
57,500
+7,500
+15% +$1.02M 0.05% 351
2017
Q2 		$6.08M Buy
+50,000
New +$5.82M 0.04% 447
2016
Q3 		– Sell
-1,400
Closed -$163K – 2543
2016
Q2 		$163K Buy
+1,400
New +$199K ﹤0.01% 1860
2016
Q1 		– Sell
-32,500
Closed -$6.2M – 2687
2015
Q4 		$6.2M Hold
32,500
– – 0.04% 377
2015
Q3 		$5.08M Sell
32,500
-60,900
-65% -$11.1M 0.03% 479
2015
Q2 		$16.9M Buy
+93,400
New +$16.1M 0.09% 190
2014
Q1 		– Sell
-17,000
Closed -$2.26M – 2474
2013
Q4 		$2.26M Sell
17,000
-28,900
-63% -$3.47M 0.01% 538
2013
Q3 		$5.33M Buy
+45,900
New +$5.04M 0.05% 310

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Jefferies Group's ALXN Position: Q3 2021 in Review

Jefferies Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 57,500 shares — an estimated $10.6M sold.

Jefferies Group first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $13.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jefferies Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 57,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10.6M.
  • Jefferies Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Jefferies Group's Alexion Pharmaceuticals position peaked at $13.4M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.